
|Articles|June 20, 2019
June 2019 Digital Edition
Advertisement
Pipeline watch: we look closely at drugs in phase 2, phase 3 or recently approved for basal cell carcinoma and melanoma. Plus, treating patients with autism, and the physician's impact on regulations and pay.
Subscribe to Dermatology Times!
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















